CDH2 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, BM derived MSCs preserve from elimination LSCs of CML when treated by a tyrosine kinase inhibitor through induction of N-cadherin and activation of wnt/β-catenin23.